A 39-year-old nulliparous woman with heavy menstrual bleeding undergoes hysteroscopy and endometrial biopsy. Histology shows endometrial hyperplasia without atypia. She has a body mass index of 36 kg/m² and has polycystic ovary syndrome. She wishes to preserve her fertility. What is the most appropriate management?
Q22
A 27-year-old woman is being monitored for a suspected ectopic pregnancy. Her initial serum beta-hCG level is 980 IU/L. A transvaginal ultrasound scan shows an empty uterus with no adnexal masses visible and no free fluid. She is haemodynamically stable with minimal abdominal discomfort. A repeat beta-hCG level 48 hours later is 1420 IU/L. What is the most appropriate next step in management?
Q23
A 44-year-old woman presents with heavy menstrual bleeding. She reports flooding and passing large clots. Her periods last 8 days and occur every 28 days. She has completed her family and declines hormonal treatments. Pelvic examination is normal. Transvaginal ultrasound shows a normal anteverted uterus measuring 8 cm with a homogeneous endometrium of 6 mm. Full blood count reveals haemoglobin of 95 g/L. Which of the following is the most appropriate initial pharmacological management?
Q24
A 49-year-old woman presents with a 13-month history of increasingly heavy and prolonged menstrual bleeding. Over the past 3 months, she has noticed bleeding occurring between periods as well. Examination reveals a slightly bulky uterus. Transvaginal ultrasound shows an endometrial thickness of 18 mm and a normal myometrium. She has a BMI of 33 kg/m², takes metformin for type 2 diabetes, and has a 20 pack-year smoking history. What is the most appropriate next investigation?
Q25
A 33-year-old woman presents with left iliac fossa pain and 7 weeks amenorrhoea. Her observations are: blood pressure 124/78 mmHg, pulse 76 bpm, temperature 37.1°C. Transvaginal ultrasound shows an empty uterus with a 28 mm left adnexal mass containing a fetal pole with cardiac activity. There is minimal free fluid in the pouch of Douglas. Serum beta-hCG is 5,200 IU/L. She has no previous abdominal surgery and wishes to conceive again in future. What factor most significantly reduces the likelihood of successful medical management with methotrexate?
Q26
A 41-year-old woman with heavy menstrual bleeding has been using a levonorgestrel intrauterine system for 18 months. Her bleeding has improved significantly but she continues to have irregular spotting on 10-15 days per month which she finds bothersome. Pelvic examination confirms the IUS threads are visible and the device is correctly positioned. Transvaginal ultrasound shows the IUS in the correct position within the uterine cavity, a uniform endometrial thickness of 4 mm, and no structural abnormalities. What is the most appropriate management?
Q27
A 38-year-old woman presents with a 16-month history of heavy menstrual bleeding. She reports flooding and clots, requiring pad changes every 1-2 hours on the heaviest days. Examination reveals a 14-week size uterus which is non-tender. Transvaginal ultrasound demonstrates multiple intramural and subserosal fibroids, the largest measuring 6 cm. Endometrial thickness is 8 mm. Haemoglobin is 97 g/L. She has completed her family. Medical management with tranexamic acid and levonorgestrel IUS has been ineffective. What is the most appropriate next treatment option?
Q28
A 32-year-old woman with 6 weeks amenorrhoea presents with minimal vaginal spotting. Transvaginal ultrasound shows an empty uterus with 8 mm endometrial thickness and a 22 mm right adnexal mass containing a yolk sac but no fetal pole. There is no free fluid. Serum beta-hCG is 1,850 IU/L. She is clinically stable and wishes to avoid surgery if possible. What is the most appropriate management approach?
Q29
According to the Royal College of Obstetricians and Gynaecologists guidance, what is the definition of heavy menstrual bleeding that should prompt investigation and treatment?
Q30
A 29-year-old woman undergoes laparoscopy for suspected ectopic pregnancy. Intraoperatively, a 25 mm unruptured right ampullary ectopic pregnancy is identified. Both fallopian tubes appear normal with no evidence of hydrosalpinx or adhesions. The patient has no history of subfertility and has one previous uncomplicated vaginal delivery. She wishes to have more children. What is the most appropriate surgical management?
Gynaecology UK Medical PG Practice Questions and MCQs
Question 21: A 39-year-old nulliparous woman with heavy menstrual bleeding undergoes hysteroscopy and endometrial biopsy. Histology shows endometrial hyperplasia without atypia. She has a body mass index of 36 kg/m² and has polycystic ovary syndrome. She wishes to preserve her fertility. What is the most appropriate management?
A. Levonorgestrel intrauterine system with regular endometrial surveillance (Correct Answer)
B. Total hysterectomy with bilateral salpingo-oophorectomy
C. Endometrial ablation
D. Cyclical oral progestogen therapy with metformin
E. Combined oral contraceptive pill
Explanation: ***Levonorgestrel intrauterine system with regular endometrial surveillance***
- The **LNG-IUS** is the first-line treatment for **endometrial hyperplasia without atypia** because it provides high local progestogen concentrations, leading to a higher **regression rate** compared to oral therapy.
- It addresses both the **heavy menstrual bleeding** and the hyperplasia while preserving **fertility**, with repeat biopsy surveillance required every **6 months**.
*Total hysterectomy with bilateral salpingo-oophorectomy*
- This is an over-treatment for **hyperplasia without atypia** and is generally reserved for cases with **atypia** or failed medical management.
- Choosing this option would result in the permanent loss of **fertility**, which contradicts the patient's expressed desire to preserve it.
*Endometrial ablation*
- This procedure is **contraindicated** in the management of endometrial hyperplasia because it can lead to **intrauterine adhesions** that prevent future endometrial sampling.
- Subsequent **endometrial surveillance** becomes impossible, potentially masking the progression of any remaining deeper hyperplastic tissue to **malignancy**.
*Cyclical oral progestogen therapy with metformin*
- While **oral progestogens** are used to treat hyperplasia, **cyclical** therapy is significantly less effective than **continuous** progestogen or the LNG-IUS in achieving regression.
- **Metformin** may help manage her **PCOS** and metabolic profile, but it is not a primary or standalone treatment for histologically confirmed **endometrial hyperplasia**.
*Combined oral contraceptive pill*
- The **COCP** is less effective than the LNG-IUS for treating established endometrial hyperplasia and carries increased risks due to her **BMI of 36 kg/m²**.
- The **estrogen component** of the pill may be undesirable when trying to counteract a state of **unopposed estrogen** causing the hyperplasia.
Question 22: A 27-year-old woman is being monitored for a suspected ectopic pregnancy. Her initial serum beta-hCG level is 980 IU/L. A transvaginal ultrasound scan shows an empty uterus with no adnexal masses visible and no free fluid. She is haemodynamically stable with minimal abdominal discomfort. A repeat beta-hCG level 48 hours later is 1420 IU/L. What is the most appropriate next step in management?
A. Administer intramuscular methotrexate and arrange follow-up
B. Repeat serum beta-hCG in a further 48 hours (Correct Answer)
C. Arrange urgent diagnostic laparoscopy
D. Repeat transvaginal ultrasound scan in 7-14 days
E. Expectant management with weekly beta-hCG monitoring
Explanation: ***Repeat serum beta-hCG in a further 48 hours***
- The patient has a **pregnancy of unknown location (PUL)** with a beta-hCG rise of approximately **45%** over 48 hours, which is suboptimal but inconclusive.
- Since the current level (1420 IU/L) is just below the typical **discriminatory zone** (1500–2000 IU/L) for ultrasound visualization, a repeat test is needed to clarify if the pregnancy is **viable**, **ectopic**, or **failing**.
*Administer intramuscular methotrexate and arrange follow-up*
- **Methotrexate** is contraindicated until a diagnosis of **ectopic pregnancy** is confirmed and a viable intrauterine pregnancy is strictly ruled out.
- Intervening at this stage carries the risk of inadvertently terminating a potentially **viable intrauterine pregnancy** that is simply rising slowly.
*Arrange urgent diagnostic laparoscopy*
- Surgical intervention is not indicated because the patient is **haemodynamically stable** with minimal symptoms and no imaging evidence of an ectopic mass.
- **Laparoscopy** is an invasive procedure generally reserved for unstable patients or cases where there is high clinical suspicion with supporting scan findings.
*Repeat transvaginal ultrasound scan in 7-14 days*
- Waiting up to 14 days is inappropriate for a **suspected ectopic pregnancy** due to the risk of **tubal rupture** as levels continue to rise.
- Repeat imaging is typically scheduled once the **beta-hCG** has crossed the discriminatory threshold or if symptoms change, rather than a fixed long-term delay.
*Expectant management with weekly beta-hCG monitoring*
- **Expectant management** (weekly monitoring) is only appropriate if beta-hCG levels are **low and decreasing** (typically <1000 IU/L and falling).
- In this case, the levels are **increasing**, which requires more frequent monitoring (every 48 hours) to ensure patient safety and diagnostic accuracy.
Question 23: A 44-year-old woman presents with heavy menstrual bleeding. She reports flooding and passing large clots. Her periods last 8 days and occur every 28 days. She has completed her family and declines hormonal treatments. Pelvic examination is normal. Transvaginal ultrasound shows a normal anteverted uterus measuring 8 cm with a homogeneous endometrium of 6 mm. Full blood count reveals haemoglobin of 95 g/L. Which of the following is the most appropriate initial pharmacological management?
A. Tranexamic acid 1 g three times daily during menstruation (Correct Answer)
B. Mefenamic acid 500 mg three times daily during menstruation
C. Combined oral contraceptive pill
D. Norethisterone 5 mg three times daily from day 5 to 26 of cycle
E. Gonadotrophin-releasing hormone agonist
Explanation: ***Tranexamic acid 1 g three times daily during menstruation***
- **Tranexamic acid** is the most effective **non-hormonal** treatment for **heavy menstrual bleeding (HMB)**, working by inhibiting **fibrinolysis** to reduce blood loss by 40-50%.
- Given the patient's explicit **declination of hormonal treatments** and confirmed anemia (Hb 95 g/L), tranexamic acid is the appropriate first-line pharmacological choice.
*Mefenamic acid 500 mg three times daily during menstruation*
- This **NSAID** reduces blood loss by inhibiting **prostaglandin synthesis** but is generally less effective than tranexamic acid, offering only a 20-30% reduction.
- While it's a non-hormonal option and can be used for HMB, especially if **dysmenorrhea** is present, it is not considered the *most appropriate initial* pharmacological management specifically for heavy flow when tranexamic acid is available.
*Combined oral contraceptive pill*
- The **combined oral contraceptive pill** is an effective hormonal treatment that helps to regulate the menstrual cycle and significantly reduces menstrual blood loss by thinning the **endometrium**.
- However, this option is unsuitable as the patient has explicitly **declined all hormonal treatments** for her heavy menstrual bleeding.
*Norethisterone 5 mg three times daily from day 5 to 26 of cycle*
- High-dose **progestogens** like norethisterone can reduce heavy menstrual bleeding by stabilizing the **endometrium**.
- This treatment is a **hormonal intervention**, making it an inappropriate choice for a patient who has clearly stated her preference to avoid hormonal therapies.
*Gonadotrophin-releasing hormone agonist*
- **GnRH agonists** induce a temporary hypoestrogenic state, essentially creating a medical menopause, which effectively stops menstruation.
- These agents are typically reserved for severe, refractory cases of HMB, often associated with fibroids, or for **preoperative** use, and are not considered initial management for uncomplicated heavy menstrual bleeding due to their significant side effects and hormonal nature.
Question 24: A 49-year-old woman presents with a 13-month history of increasingly heavy and prolonged menstrual bleeding. Over the past 3 months, she has noticed bleeding occurring between periods as well. Examination reveals a slightly bulky uterus. Transvaginal ultrasound shows an endometrial thickness of 18 mm and a normal myometrium. She has a BMI of 33 kg/m², takes metformin for type 2 diabetes, and has a 20 pack-year smoking history. What is the most appropriate next investigation?
A. MRI pelvis to further characterise the endometrium
B. Hysteroscopy and endometrial biopsy (Correct Answer)
C. Repeat transvaginal ultrasound in the early proliferative phase
D. Outpatient endometrial pipelle biopsy
E. Serum CA-125
Explanation: ***Hysteroscopy and endometrial biopsy***
- This patient presents with **abnormal uterine bleeding**, **obesity (BMI 33)**, and **type 2 diabetes**, which are significant risk factors for **endometrial hyperplasia** or **malignancy**.
- An **endometrial thickness of 18 mm** is highly abnormal and requires a **hysteroscopy** to allow for direct visualization of focal lesions and targeted histological sampling.
*MRI pelvis to further characterise the endometrium*
- MRI is generally used for **staging** known endometrial cancer rather than as a primary tool for the initial diagnosis of abnormal bleeding.
- It cannot provide a **histological diagnosis**, which is mandatory to rule out cancer in a patient with a thickness of 18 mm.
*Repeat transvaginal ultrasound in the early proliferative phase*
- Delaying further investigation with a repeat scan is inappropriate when the **endometrium is 18 mm**, especially in a perimenopausal woman with risk factors.
- Clinical guidelines mandate **tissue sampling** whenever there is persistent intermenstrual bleeding or a significantly thickened endometrial stripe.
*Outpatient endometrial pipelle biopsy*
- While pipelle biopsy is a valid tool, its sensitivity is lower for **focal pathology** like polyps, which are likely given the "bulky uterus" and intermenstrual bleeding.
- **Hysteroscopy** is the superior investigation in this scenario as it ensures the entire cavity is assessed and biopsy is directed toward the most suspicious areas.
*Serum CA-125*
- CA-125 is a marker primarily used for **ovarian cancer** screening/monitoring and has no diagnostic role in the initial workup of **abnormal uterine bleeding**.
- It lacks the specificity needed for endometrial assessment and cannot substitute for **endometrial sampling**.
Question 25: A 33-year-old woman presents with left iliac fossa pain and 7 weeks amenorrhoea. Her observations are: blood pressure 124/78 mmHg, pulse 76 bpm, temperature 37.1°C. Transvaginal ultrasound shows an empty uterus with a 28 mm left adnexal mass containing a fetal pole with cardiac activity. There is minimal free fluid in the pouch of Douglas. Serum beta-hCG is 5,200 IU/L. She has no previous abdominal surgery and wishes to conceive again in future. What factor most significantly reduces the likelihood of successful medical management with methotrexate?
A. Beta-hCG level of 5,200 IU/L
B. Size of ectopic pregnancy (28 mm)
C. Presence of fetal cardiac activity (Correct Answer)
D. Left-sided location of the ectopic pregnancy
E. Presence of free fluid in pouch of Douglas
Explanation: ***Presence of fetal cardiac activity***
- The presence of **fetal cardiac activity** is a significant negative prognostic factor for **methotrexate** success, as it indicates a more viable and metabolically active trophoblastic tissue.
- This factor significantly reduces the likelihood of successful medical management, often leading to **treatment failure** and requiring surgical intervention.
*Beta-hCG level of 5,200 IU/L*
- While lower **hCG levels** (typically <3,000-5,000 IU/L) are associated with higher methotrexate success rates, a level of 5,200 IU/L is a relative concern but not an absolute contraindication, especially when compared to cardiac activity.
- The presence of **cardiac activity** carries a much higher predictive value for methotrexate failure than this specific hCG level alone.
*Size of ectopic pregnancy (28 mm)*
- Medical management with **methotrexate** is generally considered appropriate for ectopic pregnancies with a maximum diameter of **3.5 cm (35 mm)**.
- A 28 mm ectopic mass falls within the acceptable size criteria for medical management, making it a less significant factor for failure.
*Left-sided location of the ectopic pregnancy*
- The **anatomic location** of the ectopic pregnancy (left versus right) does not influence the efficacy or success rate of **systemic methotrexate** treatment.
- This is a descriptive finding and has no bearing on the choice or success of medical management.
*Presence of free fluid in pouch of Douglas*
- Minimal **free fluid** in the pouch of Douglas is a common finding in ectopic pregnancy and does not necessarily indicate **tubal rupture** or preclude medical management in a stable patient.
- Only significant amounts of **free fluid** or signs of **hemodynamic instability** would prompt immediate surgical intervention.
Question 26: A 41-year-old woman with heavy menstrual bleeding has been using a levonorgestrel intrauterine system for 18 months. Her bleeding has improved significantly but she continues to have irregular spotting on 10-15 days per month which she finds bothersome. Pelvic examination confirms the IUS threads are visible and the device is correctly positioned. Transvaginal ultrasound shows the IUS in the correct position within the uterine cavity, a uniform endometrial thickness of 4 mm, and no structural abnormalities. What is the most appropriate management?
A. Removal of the IUS and insertion of a new device
B. Addition of cyclical oral progestogen therapy
C. Reassurance and continuation of current management (Correct Answer)
D. Hysteroscopy to check for endometrial polyps
E. Removal of the IUS and commencement of tranexamic acid
Explanation: ***Reassurance and continuation of current management***
- Irregular **spotting** is a common and expected side effect of the **levonorgestrel intrauterine system (LNG-IUS)**, even after the initial 6-month stabilization period.
- Since the device is **correctly positioned**, ultrasound shows a thin **4 mm endometrium**, and heavy bleeding has improved, no further intervention is medically required.
*Removal of the IUS and insertion of a new device*
- There is no evidence of **device displacement** or failure; therefore, replacing it would not resolve the hormonal side effect of spotting.
- This approach unnecessarily exposes the patient to the risks and discomfort of a **re-insertion procedure**.
*Addition of cyclical oral progestogen therapy*
- Adding **cyclical progestogens** to an LNG-IUS is not a standard evidence-based treatment for spotting and may further destabilize the **endometrium**.
- This increases the pill burden and systemic side effects without guaranteeing a reduction in **unscheduled bleeding**.
*Hysteroscopy to check for endometrial polyps*
- **Transvaginal ultrasound** has already confirmed a uniform **4 mm endometrium** and no structural abnormalities, making polyps highly unlikely.
- **Hysteroscopy** is an invasive procedure and is not indicated when non-invasive imaging has already ruled out **intrauterine pathology**.
*Removal of the IUS and commencement of tranexamic acid*
- **Tranexamic acid** is used only during active heavy bleeding and is ineffective for managing the **intermittent spotting** caused by progestogens.
- Removing the IUS would likely cause a return of the patient's **heavy menstrual bleeding**, which was her primary clinical concern.
Question 27: A 38-year-old woman presents with a 16-month history of heavy menstrual bleeding. She reports flooding and clots, requiring pad changes every 1-2 hours on the heaviest days. Examination reveals a 14-week size uterus which is non-tender. Transvaginal ultrasound demonstrates multiple intramural and subserosal fibroids, the largest measuring 6 cm. Endometrial thickness is 8 mm. Haemoglobin is 97 g/L. She has completed her family. Medical management with tranexamic acid and levonorgestrel IUS has been ineffective. What is the most appropriate next treatment option?
A. Uterine artery embolisation
B. Total abdominal hysterectomy (Correct Answer)
C. GnRH agonist therapy for 6 months
D. Myomectomy
E. Endometrial ablation
Explanation: ***Total abdominal hysterectomy***
- This is the most appropriate **definitive treatment** for a woman who has **completed her family**, failed medical management, and has a significantly enlarged **14-week size uterus** due to fibroids.
- It provides a permanent solution to **heavy menstrual bleeding (HMB)**, corrects **anaemia** over time, and eliminates the risk of **fibroid recurrence** or the need for further procedures.
*Uterine artery embolisation*
- While effective for shrinking fibroids and reducing bleeding, it is typically preferred by women who wish to **preserve their uterus** or **avoid major surgery**, which is not a primary concern for this patient who has completed her family.
- It carries a higher risk of **treatment failure** or the need for future re-intervention compared to a hysterectomy, and a 14-week size uterus with a 6 cm fibroid might have a less predictable response.
*GnRH agonist therapy for 6 months*
- These are primarily used as **pre-operative adjuncts** to temporarily shrink fibroids and correct **anaemia** before surgery, rather than as a long-term definitive treatment.
- Symptoms usually recur rapidly once the medication is stopped, and extended use is limited by side effects like **bone mineral density loss** and menopausal symptoms.
*Myomectomy*
- This surgical option is specifically indicated for women with fibroids who **wish to preserve fertility** or the uterus, which is not a priority for this patient who has completed her family.
- It is a more complex surgical procedure with potential for **significant blood loss** and does not prevent the growth of new fibroids, meaning recurrence of symptoms is possible.
*Endometrial ablation*
- This procedure is generally **contraindicated** in this patient because her uterus is larger than **10-12 weeks size** and contains fibroids greater than **3 cm**, especially intramural or subserosal ones.
- Ablation is significantly less effective when the **uterine cavity is distorted** by large fibroids, and for subserosal fibroids, it would not address the issue.
Question 28: A 32-year-old woman with 6 weeks amenorrhoea presents with minimal vaginal spotting. Transvaginal ultrasound shows an empty uterus with 8 mm endometrial thickness and a 22 mm right adnexal mass containing a yolk sac but no fetal pole. There is no free fluid. Serum beta-hCG is 1,850 IU/L. She is clinically stable and wishes to avoid surgery if possible. What is the most appropriate management approach?
A. Immediate laparoscopic salpingectomy
B. Single-dose intramuscular methotrexate 50 mg/m² with day 4 and 7 beta-hCG monitoring (Correct Answer)
C. Expectant management with serial beta-hCG and ultrasound
D. Two-dose methotrexate regimen with days 0, 4, and 7 beta-hCG monitoring
E. Uterine curettage to exclude intrauterine pregnancy
Explanation: ***Single-dose intramuscular methotrexate 50 mg/m² with day 4 and 7 beta-hCG monitoring***- The patient is a suitable candidate for **medical management** as she is **haemodynamically stable**, has an adnexal mass **<3.5 cm** (22 mm), **no fetal heartbeat**, and a **beta-hCG <5,000 IU/L** (1,850 IU/L).- The **single-dose protocol** is the first-line medical intervention for eligible patients, requiring monitoring on days 4 and 7 to ensure a **≥15% decline** in beta-hCG levels from day 0 to day 4, or day 4 to day 7.*Immediate laparoscopic salpingectomy*- Surgical intervention is typically reserved for patients who are **clinically unstable**, have signs of **tubal rupture**, or have **beta-hCG levels >5,000 IU/L** with fetal cardiac activity.- Since the patient is **clinically stable** and meets all criteria for medical management, along with expressing a wish to **avoid surgery**, immediate laparoscopy is not indicated.*Expectant management with serial beta-hCG and ultrasound*- Expectant management is generally considered only when **beta-hCG levels are low** (typically <1,000-1,500 IU/L) and are already spontaneously declining.- The presence of a **yolk sac** and beta-hCG of **1,850 IU/L** indicates active trophoblastic tissue, making spontaneous resolution less likely and carrying a significant risk of rupture without intervention.*Two-dose methotrexate regimen with days 0, 4, and 7 beta-hCG monitoring*- A **two-dose methotrexate regimen** is usually reserved for cases where the initial **beta-hCG is higher** (e.g., 3,000-5,000 IU/L) or if the single-dose protocol fails to achieve the required decline.- Given the beta-hCG of **1,850 IU/L**, the **single-dose protocol** is the standard and preferred approach to minimize drug toxicity and side effects.*Uterine curettage to exclude intrauterine pregnancy*- **Uterine curettage** is unnecessary here because the **transvaginal ultrasound** has already definitively identified an **adnexal mass with a yolk sac**, confirming an ectopic pregnancy.- This procedure is primarily used in cases of **pregnancy of unknown location (PUL)** with rising hCG where an intrauterine pregnancy cannot be excluded, not when an ectopic pregnancy is clearly visualized.
Question 29: According to the Royal College of Obstetricians and Gynaecologists guidance, what is the definition of heavy menstrual bleeding that should prompt investigation and treatment?
A. Menstrual blood loss exceeding 80 mL per cycle
B. Menstrual blood loss that interferes with the woman's physical, emotional, social and material quality of life (Correct Answer)
C. Menstrual periods lasting longer than 7 days
D. Requiring the use of more than 16 pads or tampons per menstrual cycle
E. Haemoglobin level less than 120 g/L in association with menstrual bleeding
Explanation: ***Menstrual blood loss that interferes with the woman's physical, emotional, social and material quality of life***
- The **Royal College of Obstetricians and Gynaecologists (RCOG)**, in line with **NICE guidelines**, defines heavy menstrual bleeding based on its subjective impact on a woman's **quality of life**.
- This definition recognizes that the patient's perception of her bleeding and its disruption to her daily activities is the primary indicator for investigation and treatment.
*Menstrual blood loss exceeding 80 mL per cycle*
- While 80 mL was historically used as an **objective measure** in research, it is **impractical** to accurately quantify blood loss in routine clinical practice.
- This definition does not fully encompass the individual variation in how women experience and are affected by their menstrual flow.
*Menstrual periods lasting longer than 7 days*
- This describes **prolonged menstrual bleeding**, which can coexist with heavy bleeding but is not the sole defining characteristic of heavy menstrual bleeding that warrants investigation.
- A woman can experience significant heavy bleeding in a shorter duration that still severely impacts her **quality of life**, necessitating intervention.
*Requiring the use of more than 16 pads or tampons per menstrual cycle*
- The number of **sanitary products** used can be a useful clinical indicator for assessing menstrual volume, but it is not a standardized or definitive criterion for diagnosis.
- This method is highly variable, depending on product absorbency, individual habits, and does not directly capture the **personal impact** of the bleeding.
*Haemoglobin level less than 120 g/L in association with menstrual bleeding*
- A low **haemoglobin level**, indicating **anaemia**, is a common *consequence* of heavy menstrual bleeding and a reason for intervention, but it is not the definition of the condition itself.
- Many women experience significant disruption to their lives due to heavy bleeding long before their **haemoglobin levels** drop to an anaemic range.
Question 30: A 29-year-old woman undergoes laparoscopy for suspected ectopic pregnancy. Intraoperatively, a 25 mm unruptured right ampullary ectopic pregnancy is identified. Both fallopian tubes appear normal with no evidence of hydrosalpinx or adhesions. The patient has no history of subfertility and has one previous uncomplicated vaginal delivery. She wishes to have more children. What is the most appropriate surgical management?
A. Right salpingectomy
B. Right salpingotomy with tubal lavage
C. Right salpingotomy without tubal lavage (Correct Answer)
D. Bilateral salpingectomy
E. Right cornual resection
Explanation: ***Right salpingotomy without tubal lavage***
- **Salpingotomy** is the preferred surgical approach for an **unruptured ectopic pregnancy** in patients who desire **future fertility** and have healthy contralateral tubes. It allows for the removal of the ectopic while preserving the integrity of the fallopian tube.
- Current evidence and guidelines, such as those from the RCOG, do not recommend **tubal lavage** after salpingotomy, as it has not been shown to improve subsequent fertility outcomes and may increase the risk of **tubal damage** or prolong operative time unnecessarily.
*Right salpingectomy*
- This procedure involves the **complete removal** of the fallopian tube. While it is a definitive treatment for ectopic pregnancy, it reduces the patient's future fertility potential, which goes against her expressed wish for **more children**.
- **Salpingectomy** is typically indicated for ruptured ectopic pregnancies, recurrent ectopics in the same tube, severely damaged tubes, or in patients who do not desire future fertility.
*Right salpingotomy with tubal lavage*
- While **salpingotomy** aims to preserve fertility by saving the tube, the addition of **tubal lavage** (flushing the tube) is not supported by current clinical guidelines.
- Studies have shown that lavage does not improve the chances of a successful **intrauterine pregnancy** or reduce the risk of future **ectopic pregnancy**, making it an unnecessary step.
*Bilateral salpingectomy*
- This surgical option would result in **permanent sterilization**, as both fallopian tubes would be removed. This directly contradicts the patient's clear desire to have **more children**.
- **Bilateral salpingectomy** is reserved for specific indications, such as bilateral tubal disease, or as a method of permanent contraception.
*Right cornual resection*
- **Cornual resection** is a highly specific procedure indicated for **interstitial** or **cornual pregnancies**, which implant within the muscular wall of the uterus at the utero-tubal junction.
- The patient in this scenario has an **ampullary ectopic pregnancy**, which is located in the widest part of the fallopian tube, making cornual resection anatomically inappropriate and unnecessarily invasive for this type of ectopic.
